2015 American Transplant Congress
Rabbit Antithymocyte Globulin Is Associated With Improved Patient and Graft Survival in Liver Transplantation. Experience With 595 Patients
BACKGROUND: Use of induction therapy in liver transplantation is debatable. We aimed to compare clinical outcomes of different induction protocols in liver transplant recipients.METHODS: Retrospective…2015 American Transplant Congress
Thymoglobulin Administration During Multi-Visceral and Isolated Small Bowel Procurement Does Not Adversely Affect the Survival of Harvested Organs
Anti-thymocyte globulin administration in donors before intestinal procurement may result in decreased graft versus-host disease (GVHD) due to reduced recipient lymphocyte trafficking after reperfusion. Reluctance…2015 American Transplant Congress
Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus
AIM:Immunosuppression with an mTOR inhibitor plus calcineurin inhibitor (CNI) minimization is increasingly used in liver transplantation to protect against the nephrotoxic and neurotoxic side effects…2015 American Transplant Congress
Current Status of US Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Intestine Transplant Registry
The purpose of this study is to analyze the current status of US intestinal transplantation (IT). As of 9/19/2014, 2441 IT have been performed in…2015 American Transplant Congress
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype
1University Medicine Charité, Berlin, Germany; 2Labor Berlin GmbH, Berlin, Germany.
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result…2015 American Transplant Congress
Immune Phenotyping of Peripheral Blood Samples from the CTOT-10 Belatacept Study
The purpose of the CTOT-10 study is to evaluate belatacept as maintenance therapy, while minimizing calcineurin inhibitors and corticosteroids in renal transplantation. We designed mechanistic…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Pyridoxine Deficiency After Solid Organ Transplant
BackgroundMicronutrient deficiencies have been discussed in the literature regarding post-transplant recipients. A proposed theory is that immunosuppressive medications or altered immune system cause pyridoxine deficiency…2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Mycophenolate Dose Reductions Contribute to Suboptimal Graft Outcomes in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC.
The purpose of this study was to analyze outcomes in patients with mycophenolate mofetil (MMF) dose reductions below doses proven to prevent rejection in a…
American Transplant Congress abstracts